title: How I treat catastrophic thrombotic syndromes.
abstract: Catastrophic thrombotic syndromes are characterized by rapid onset of multiple thromboembolic occlusions affecting diverse vascular beds. Patients may have multiple events on presentation, or develop them rapidly over days to weeks. Several disorders can present with this extreme clinical phenotype, including catastrophic antiphospholipid syndrome (APS), atypical presentations of thrombotic thrombocytopenic purpura (TTP) or heparin-induced thrombocytopenia (HIT), and Trousseau syndrome, but some patients present with multiple thrombotic events in the absence of associated prothrombotic disorders. Diagnostic workup must rapidly determine which, if any, of these syndromes are present because therapeutic management is driven by the underlying disorder. With the exception of atypical presentations of TTP, which are treated with plasma exchange, anticoagulation is the most important therapeutic intervention in these patients. Effective anticoagulation may require laboratory confirmation with anti-factor Xa levels in patients treated with heparin, especially if the baseline (pretreatment) activated partial thromboplastin time is prolonged. Patients with catastrophic APS also benefit from immunosuppressive therapy and/or plasma exchange, whereas patients with HIT need an alternative anticoagulant to replace heparin. Progressive thrombotic events despite therapeutic anticoagulation may necessitate an alternative therapeutic strategy. If the thrombotic process can be controlled, these patients can recover, but indefinite anticoagulant therapy may be appropriate to prevent recurrent events.
authors.affiliation: Division of Hematology, Departments of Medicine and Pathology, Duke University Medical Center, Durham, NC;
authors.forename: Thomas L
authors.identifier: http://orcid.org/0000-0001-6193-4585
authors.initials: TL
authors.lastname: Ortel
authors.affiliation: Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY; and.
authors.forename: Doruk
authors.initials: D
authors.lastname: Erkan
authors.affiliation: Division of Hematology, University of Florida, Gainesville, FL.
authors.forename: Craig S
authors.initials: CS
authors.lastname: Kitchens
mesh_terms: D000293:Adolescent; D000925:Anticoagulants / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000628:therapy; D002388:Catastrophic Illness; D005260:Female; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D008297:Male; D010951:Plasma Exchange; D011247:Pregnancy; D011697:Purpura, Thrombotic Thrombocytopenic / Q000628:therapy; D013577:Syndrome; D013921:Thrombocytopenia / Q000139:chemically induced / Q000628:therapy; D013927:Thrombosis / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*
chemical_list: D000925:Anticoagulants; D006493:Heparin